Search results
Found 30520 matches for
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Trials Expertise Session: The role of a Trial Manager in a Trial Management Group (TMG) *online*
Thursday, 12 June 2025, 10am to 11am
Trials Expertise Session: Communication skills in Clinical Trials for Trial Managers *online*
Wednesday, 26 March 2025, 10am to 11am
Trials Expertise Session: Site Feasibility Questionnaires (SFQ) & Site selection *Hybrid*
Wednesday, 25 June 2025, 11am to 12pm
Meet Chris
-
Christopher Buckley
Kennedy Professor of Translational Rheumatology and Director of Clinical Research
